{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:07:52Z","timestamp":1793876872845,"version":"4.7.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007110","name":"Schering-Plough","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RG3008"],"award-info":[{"award-number":["RG3008"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RG008\/08"],"award-info":[{"award-number":["RG008\/08"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"NIHR Clinical Lectureship","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008721","name":"UCLH NIHR BRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.atherosclerosis.2018.11.014","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T07:39:54Z","timestamp":1542008394000},"page":"207-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register"],"prefix":"10.1016","volume":"281","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8221-6547","authenticated-orcid":false,"given":"Steve E.","family":"Humphries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Capps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul N.","family":"Durrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian F.W.","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handrean","family":"Soran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.W.","family":"Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00109-005-0019-z","article-title":"Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing","volume":"84","author":"Humphries","year":"2006","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib2","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"issue":"7635","key":"10.1016\/j.atherosclerosis.2018.11.014_bib3","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0140-6736(69)90930-1","article-title":"Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states","volume":"2","author":"Slack","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/01.CIR.49.3.476","article-title":"Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia","volume":"49","author":"Stone","year":"1974","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib5","first-page":"13","article-title":"Heterozygous familial hypercholesterolemia. Relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women","volume":"34","author":"Gagne","year":"1979","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"10","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"The risk of fatal coronary heart disease in familial hypercholesterolaemia","volume":"303","author":"Scientific Steering Committee on behalf of Simon Broome Familial Hyperlipidaemia Register Group","year":"1991","journal-title":"B M J"},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0021-9150(98)00200-7","article-title":"Scientific Steering Committee on behalf of the Simon Broome Register Group - mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management","volume":"142","author":"Betteridge","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2004.10.011","article-title":"Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"179","author":"Neil","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2018.04.040","article-title":"Coronary heart disease mortality in treated familial hypercholesterolaemia: update of the UK Simon Broome FH register","volume":"274","author":"Humphries","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/ije\/15.1.134","article-title":"Cohort study analysis with a FORTRAN computer program","volume":"15","author":"Coleman","year":"1986","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/hrt.2003.022764","article-title":"Risk factors for coronary heart disease in patients with heterozygous familial hypercholesterolaemia","volume":"90","author":"Neil","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib14","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib15","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.amjcard.2016.11.025","article-title":"Value of the definition of severe familial hypercholesterolemia for stratification of heterozygous patients","volume":"119","author":"Perez-Calahorra","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib17","first-page":"785","article-title":"Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal","volume":"6","author":"Carroll","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib18","first-page":"181","article-title":"Current statin treatment, DNA testing and cascade testing of UK patients with familial hypercholesterolaemia (FH): results from the Royal College of Physicians UK National audit","volume":"5","author":"Seed","year":"2012","journal-title":"Primary Care Cardiovasc. J."},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2017.05.013","article-title":"How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?","volume":"262","author":"Masana","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2017.10.006","article-title":"Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry","volume":"267","author":"Amrock","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.11.014_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/CLEP.S104258","article-title":"Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using the Health Improvement Network primary care data","volume":"8","author":"O'Keeffe","year":"2016","journal-title":"Clin. Epidemiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018314692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018314692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T01:52:25Z","timestamp":1605405145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018314692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":21,"alternative-id":["S0021915018314692"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.11.014","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}